NCT03845712View on ClinicalTrials.gov

An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 5, 2019

Primary Completion Date

February 19, 2026

Study Completion Date

February 19, 2026

Conditions

Thymidine Kinase 2 Deficiency

Interventions

DRUG

doxecitine and doxribtimine

Doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart. Doxecitine and doxribtimine is administered with food.

Trial Locations (8)

10032

Tk0102 1005, New York

Unknown

Tk0102 4038, Haifa

Tk0102 4039, Holon

Tk0102 4037, Nehariya

Tk0102 3102, Barcelona

Tk0102 3121, Esplugues de Llobregat

Tk0102 3031, Madrid

Tk0102 3101, Seville

All Listed Sponsors

lead

UCB BIOSCIENCES, Inc.

INDUSTRY